Skip to main content

Table 2 Preventive efficacy of orally administered moxidectin against macrocyclic lactone-resistant heartworm strains utilizing various dosages and dosage regimens [48]

From: Moxidectin: heartworm disease prevention in dogs in the face of emerging macrocyclic lactone resistance

Study Straina Treatmentb Dosage (µg/kg) Days of treatment Preventive efficacy (%)
1 JYD-34 Placebo 0 0, 30, 60
JYD-34 Moxidectin 3 0 19
JYD-34 Moxidectin 3 0, 30, 60 44.4
JYD-34 Moxidectin 6 0 25.5
JYD-34 Moxidectin 12 0 33.3
JYD-34 Moxidectin 24 0 53.2
2 JYD-34 Placebo 0 0, 28, 56
JYD-34 Moxidectin 24 0, 28, 56 98.8
JYD-34 Moxidectin 40 0, 28, 56 100
JYD-34 Moxidectin 60 0, 28, 56 100
ZoeLA Placebo 0 0, 28, 56
ZoeLA Moxidectin 3 0 44.4
ZoeLA Moxidectin 24 0, 28, 56 99.5
ZoeLA Moxidectin 40 0, 28, 56 99.5
ZoeLA Moxidectin 60 0 88.2
ZoeLA Moxidectin 60 0, 28, 56 100
3 ZoeMO Placebo 0 0, 28, 56
ZoeMO Moxidectin 3 0 82.1
ZoeMO Moxidectin 24 0, 28, 56 99.5
ZoeMO Moxidectin 40 0, 28, 56 100
ZoeMO Moxidectin 60 0, 28, 56 100
  1. aEach dog inoculated with 50 third-stage larvae of the specific strain ~ 1 month prior to the first treatment
  2. bFor each treatment group, n = 5